摘要
目的观察替比夫定和拉米夫定治疗HBeAg阳性慢性乙肝的疗效。方法将HBeAg阳性慢性乙肝随机分为两组。治疗组68例,给予替比夫定600mg,qd,po;;对照组62例,给予拉米夫定100mg,qd,po。结果两组分别比较ALT复常率3、6、12个月χ2值(3.254、3.625、4.322。P<0.01);HBeAg阴转率3、6、12个月χ2值(2.358、3.314、2.238。P<0.01～0.05);HBeAg血清学转换率3、6、12个月χ2值(2.327、3.318、2.828。P<0.01～0.05);HBV-DNA转阴率3、6、12个月χ2值(3.620、4.312、4.313。P<0.01)。结论两组比较,替比夫定同时提供快速、强效的HBV-DNA抑制和高HBeAg血清学转换。
Objective To investigate the efficacy of Telbivudine and Lamivudine for therapy of HBeAg positive chronic hepatitis B. Methods In this random and control study,the efficacy of Telbivudine and Lamivudine treatments were compared with HBeAg positive chronic hepatitis B.The 68 paients were assigned to a daily 600mg Telbivudine treatment.The 62 patients were assigned to a daily 100mg Lamivudine treatment.Results ALT 〈 ULN rates in 3 , 6, 12 months（χ^2=3.254,3.625,4.322.P 〈 0.01）. The clearance rates of HBeAg in 3 months, 6 months, 12 months（χ^2=2.358,3.314, 2.238.P 〈 0.01 - 0.05）.The seroconversion rates of HBeAg in 3,6, 12 months（χ^2=2.327,3.318,2.828.P 〈 0.01 - 0.05）.HBV-DNA undetectable rates in 3,6,12 months （χ^2=3.620,4.312,4.313.P〈0.01）.Gonclusion Telbivudine have quicker and more HBV-DNA undetection and more seroconversion of HBeAg.
出处
《当代医学》
2012年第36期128-129,共2页
Contemporary Medicine
